Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | PRNP | P04156 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16632058 | 0.74 | ALDH1A1 (0.68) | ALDH1A1NPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL23128175 | 0.74 | NPC1 (0.31) | NPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL9279264 | 0.71 | ALDH1A1 (0.50) | ALDH1A1NPC1RAB9ASMN1; SMN2PRNP | |
| SCHEMBL1970147 | 0.70 | RAB9A (0.38) | ALDH1A1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL9278721 | 0.69 | SRD5A2 (0.44) | ALDH1A1SMN1; SMN2SRD5A2MAPK1HTT | |
| SCHEMBL3191539 | 0.69 | L3MBTL1 (0.33) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL7464632 | 0.68 | RAB9A (0.46) | ALDH1A1NPC1RAB9ASMN1; SMN2PRNP | |
| SCHEMBL18613924 | 0.68 | TLR7 (0.68) | ALDH1A1NPC1RAB9ASMN1; SMN2SRD5A2 | |
| SCHEMBL10599614 | 0.68 | ALDH1A1 (0.52) | ALDH1A1NPC1RAB9ASMN1; SMN2PRNP | |
| SCHEMBL269233 | 0.67 | SMN1; SMN2 (0.51) | ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11267820-B2 | Tricyclic fused pyridin-2-one derivatives and their use as BRD4 inhibitors | JUBILANT BIOSYS LIMITED (IN) | 2022-03-08 | — | — | US | disclosed |
| EP-3347356-B1 | TRICYCLIC FUSED PYRIDIN-2-ONE DERIVATIVES AND THEIR USE AS BRD4 INHIBITORS | JUBILANT BIOSYS LTD (IN) | 2021-03-24 | — | — | EP | disclosed |
| EP-3347356-B1 | TRICYCLIC FUSED PYRIDIN-2-ONE DERIVATIVES AND THEIR USE AS BRD4 INHIBITORS | JUBILANT BIOSYS LTD (IN) | 2021-03-24 | — | — | EP | disclosed |
| US-20200339595-A1 | TRICYCLIC FUSED PYRIDIN-2-ONE DERIVATIVES AND THEIR USE AS BRD4 INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2020-10-29 | — | — | US | disclosed |
| US-10689395-B2 | Tricyclic fused pyridin-2-one derivatives and their use as BRD4 inhibitors | JUBILANT BIOSYS LIMITED (IN) | 2020-06-23 | — | — | US | disclosed |
| US-20180237453-A1 | TRICYCLIC FUSED PYRIDIN-2-ONE DERIVATIVES AND THEIR USE AS BRD4 INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2018-08-23 | — | — | US | disclosed |
| EP-3347356-A1 | TRICYCLIC FUSED PYRIDIN-2-ONE DERIVATIVES AND THEIR USE AS BRD4 INHIBITORS | Jubilant Biosys Limited (IN) | 2018-07-18 | — | — | EP | disclosed |
| WO-2017042834-A1 | TRICYCLIC FUSED PYRIDIN-2-ONE DERIVATIVES AND THEIR USE AS BRD4 INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2017-03-16 | — | — | WO | disclosed |
| WO-2017042834-A1 | TRICYCLIC FUSED PYRIDIN-2-ONE DERIVATIVES AND THEIR USE AS BRD4 INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2017-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339595-A1 | TRICYCLIC FUSED PYRIDIN-2-ONE DERIVATIVES AND THEIR USE AS BRD4 INHIBITORS | BRD4, BET1, BRD2 | ALDH1A1 4453/4885NPC1 2119/4885RAB9A 3557/4885 |
| US-20180237453-A1 | TRICYCLIC FUSED PYRIDIN-2-ONE DERIVATIVES AND THEIR USE AS BRD4 INHIBITORS | BRD4, BET1, BICRA | ALDH1A1 4337/4885NPC1 2177/4885RAB9A 3739/4885 |
| US-10689395-B2 | Tricyclic fused pyridin-2-one derivatives and their use as BRD4 inhibitors | BRD4, BET1, BICRA | ALDH1A1 4337/4885NPC1 2177/4885RAB9A 3739/4885 |
| US-11267820-B2 | Tricyclic fused pyridin-2-one derivatives and their use as BRD4 inhibitors | BRD4, BET1, BRD2 | ALDH1A1 4453/4885NPC1 2119/4885RAB9A 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.